Adaptive Biotechnologies raises 2026 MRD revenue guide to $276M-$286M as it targets $1,700-$1,800 ASP (NASDAQ:ADPT)

Adaptive Biotechnologies (ADPT) raised its 2026 MRD revenue guidance to $276M-$286M, targeting $1,700-$1,800 ASP. The company reported Q3 profitability ahead of expectations, with continued MRD growth, according to CEO Chad Robins.

Original reporting
Published Nov 5, 2026, 2:25 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 2:29 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$ADPT
Bullish
high confidence
Mentioned
$ADPT
Relevance
9/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$ADPTBullishHigh
01

Why it matters

The guidance raise is likely to attract new buying pressure, especially from investors focused on high‑growth biotech.

02

Market read

The new guidance is material for ADPT shareholders and may influence related biotech stocks.

03

What to watch

Potential regulatory delays or competition could temper revenue growth.

Relevance 9/10Novelty 9/10Timing: after-hours release

Background

Adaptive Biotechnologies reported a breakthrough quarter, achieving company‑wide profitability and strong MRD revenue growth.

Company-level read

Ticker impact

$ADPTBullishHigh confidence
Context

Adaptive Biotechnologies raised its 2026 MRD revenue guidance to $276M-$286M.

Expected impact

upward pressure as investors price in higher revenue outlook

Evidence & confidence

The new revenue range exceeds prior expectations and follows a profitability milestone, which typically drives buying interest.

Market effects

Boosts outlook for the broader immuno‑diagnostics sector as MRD adoption accelerates.

Positive for US biotech indices.

Limited to biotech investors; no broad market effect.

Counterpoint

If the guidance assumes optimistic reimbursement rates, the upside may be overstated.

Key entities

  • Adaptive Biotechnologies

    US‑listed biotech firm specializing in immune profiling.

Related articles

$ADPTHigh

Adaptive (ADPT) Q3 2026 Earnings Call Transcript

Adaptive (ADPT) raised its 2026 MRD revenue guidance due to strong clinical volumes and pharma revenue. Q3 saw 46% YOY growth in clinical testing volume, with 41% growth in clinical revenue. The company earned a milestone payment from Pfizer and is advancing its immune medicine separation process. Blood-based testing and community adoption of clonoSEQ increased significantly. U.S. ASP was $1,380 in Q3, with coverage gains in DLBCL and MCL.

$ADPTHigh

Adaptive Biotechnologies Corp (ADPT) Q3 2026 Earnings Call Highlights: First Profitable

Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. US ASP was $1,380, flat sequentially. The company expects no GAAP net income for Q4 or the full year. Challenges include Medicare payment structures and CMS rate uncertainties. Management remains confident in long-term pricing strategy and growth, citing favorable guidelines and market expansion.

$ADPTMedAI 8/10

Adaptive Biotechnologies Q3 Earnings Call Highlights

Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. The company raised its full-year MRD revenue outlook to $276M-$286M. Clinical testing volume increased 46% YoY, and clonoSEQ tests grew 10% sequentially. Adaptive expects 42% clinical volume growth for the year and is pursuing Medicare reimbursement updates.

$ADPTHighAI 8/10

Adaptive Biotechnologies Reports Third Quarter 2026 Financial Results

Adaptive Biotechnologies Corp (ADPT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Adaptive Biotechnologies Reports Third Quarter 2026 Financial Results SEATTLE, Nov. 04, 2026 (GLOBE NEWSWIRE) – Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genet